Ophthotech Corp. Company Profile (NASDAQ:OPHT)

About Ophthotech Corp.

Ophthotech Corp. logoOphthotech Corporation is a biopharmaceutical company. The Company specializes in the development of therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (AMD). Its advanced product candidate is Fovista, which is for use in combination with anti-vascular endothelial growth factor (VEGF) drugs. It is also developing its product candidate Zimura for the treatment of patients with geographic atrophy, a form of dry AMD, in combination with VEGF therapy for the treatment of polypoidal choroidal vasculopathy (PCV). Fovista is being tested in Phase III clinical development. In addition, it has initiated additional clinical trials to evaluate the potential additional benefits of Fovista administered in combination with anti-VEGF drugs in wet AMD patients, known as Fovista Expansion Studies. Zimura has completed a small, multicenter, uncontrolled, open label Phase I/IIa clinical trial.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: OPHT
  • CUSIP:
Key Metrics:
  • Previous Close: $52.20
  • 50 Day Moving Average: $57.66
  • 200 Day Moving Average: $50.45
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -13.63
  • P/E Growth: 0.00
  • Market Cap: $1.86B
  • Outstanding Shares: 35,593,000
  • Beta: 2.06
Additional Links:
Companies Related to Ophthotech Corp.:

Analyst Ratings

Consensus Ratings for Ophthotech Corp. (NASDAQ:OPHT) (?)
Ratings Breakdown: 1 Sell Rating, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.78)
Consensus Price Target: $89.75 (71.93% upside)

Analysts' Ratings History for Ophthotech Corp. (NASDAQ:OPHT)
Show:
DateFirmActionRatingPrice TargetDetails
8/19/2016BTIG ResearchReiterated RatingBuy$92.00View Rating Details
8/10/2016Goldman Sachs Group Inc.Reiterated RatingSell$45.00View Rating Details
8/4/2016Citigroup Inc.Boost Price TargetBuy$91.00 -> $92.00View Rating Details
7/19/2016Barclays PLCReiterated RatingBuyView Rating Details
6/2/2016JPMorgan Chase & Co.UpgradeNeutral -> Overweight$60.00 -> $84.00View Rating Details
2/24/2016Cowen and CompanyReiterated RatingBuyView Rating Details
1/27/2016Chardan CapitalReiterated RatingBuyView Rating Details
1/6/2016SunTrust Banks Inc.Initiated CoverageBuy$100.00View Rating Details
11/19/2015Oppenheimer Holdings Inc.Reiterated RatingOutperform$95.00View Rating Details
8/6/2015Stifel NicolausReiterated RatingBuy$74.00 -> $83.00View Rating Details
8/3/2015Leerink SwannReiterated RatingOutperform$69.00 -> $92.00View Rating Details
(Data available from 8/26/2014 forward)

Earnings

Earnings History for Ophthotech Corp. (NASDAQ:OPHT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016        
8/3/2016Q216($1.05)($0.85)$18.64 million$28.20 millionViewListenView Earnings Details
5/4/2016Q116($1.33)($1.03)$7.22 million$15.70 millionViewListenView Earnings Details
2/24/2016Q415($1.35)($1.02)$7.59 million$4.78 millionViewListenView Earnings Details
11/5/2015Q315($0.98)($1.14)$11.31 million$3.40 millionViewN/AView Earnings Details
8/5/2015Q215($1.02)($1.08)$2.77 million$1.60 millionViewN/AView Earnings Details
5/11/2015Q115($0.75)$0.22$3.68 million$41.70 millionViewListenView Earnings Details
2/23/2015Q414($0.57)($1.06)$12.36 million$1.68 millionViewN/AView Earnings Details
11/11/2014Q314($0.62)$0.31$8.02 million$39.58 millionViewN/AView Earnings Details
8/6/2014Q214($0.56)($1.57)$4.31 millionViewN/AView Earnings Details
5/13/2014Q1($0.67)($0.64)ViewListenView Earnings Details
2/27/2014($0.50)($0.65)ViewN/AView Earnings Details
11/13/2013Q313($1.00)($10.26)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ophthotech Corp. (NASDAQ:OPHT)
Current Year EPS Consensus Estimate: $-4.94 EPS
Next Year EPS Consensus Estimate: $-3.83 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($1.50)($1.35)($1.43)
Q2 20163($1.24)($0.66)($0.89)
Q3 20162($1.62)($1.58)($1.60)
Q4 20162($1.78)($0.51)($1.15)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ophthotech Corp. (NASDAQ:OPHT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ophthotech Corp. (NASDAQ:OPHT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/1/2016David R GuyerCEOSell24,060$64.47$1,551,148.20View SEC Filing  
7/29/2016Samir Chandrakant PatelPresidentSell20,000$64.21$1,284,200.00View SEC Filing  
7/1/2016David R GuyerCEOSell24,060$52.12$1,254,007.20View SEC Filing  
6/30/2016Samir Chandrakant PatelPresidentSell41,846$51.23$2,143,770.58View SEC Filing  
6/3/2016Axel BolteDirectorBuy3,500$56.97$199,395.00View SEC Filing  
6/2/2016Glenn SblendorioCFOSell671$57.20$38,381.20View SEC Filing  
6/1/2016David R GuyerCEOSell30,060$52.71$1,584,462.60View SEC Filing  
5/31/2016Samir Chandrakant PatelPresidentSell20,000$53.32$1,066,400.00View SEC Filing  
5/24/2016A/S NovoMajor ShareholderSell1,300,000$49.00$63,700,000.00View SEC Filing  
5/2/2016David R GuyerCEOSell22,060$46.18$1,018,730.80View SEC Filing  
4/29/2016Samir Chandrakant PatelPresidentSell20,000$46.79$935,800.00View SEC Filing  
4/1/2016David R GuyerCEOSell22,060$44.11$973,066.60View SEC Filing  
3/29/2016Samir Chandrakant PatelPresidentSell20,000$41.85$837,000.00View SEC Filing  
3/1/2016David R GuyerCEOSell22,060$45.48$1,003,288.80View SEC Filing  
2/29/2016Samir Chandrakant PatelPresidentSell20,000$45.13$902,600.00View SEC Filing  
1/29/2016Samir Chandrakant PatelPresidentSell20,000$53.59$1,071,800.00View SEC Filing  
1/28/2016David R. GuyerCEOSell18,598$53.63$997,410.74View SEC Filing  
1/11/2016Nicholas GalakatosDirectorSell3,000$65.72$197,160.00View SEC Filing  
1/4/2016Barbara A. WoodSVPSell1,000$76.37$76,370.00View SEC Filing  
12/30/2015David R. GuyerCEOSell18,582$78.82$1,464,633.24View SEC Filing  
12/30/2015Glenn SblendorioDirectorSell2,000$80.00$160,000.00View SEC Filing  
12/29/2015Samir Chandrakant PatelPresidentSell1,184$77.50$91,760.00View SEC Filing  
12/24/2015Samir Chandrakant PatelPresidentSell26,036$77.09$2,007,115.24View SEC Filing  
12/10/2015Nicholas GalakatosDirectorSell3,000$64.44$193,320.00View SEC Filing  
12/1/2015Barbara A. WoodSVPSell2,000$63.24$126,480.00View SEC Filing  
11/30/2015David R. GuyerCEOSell18,582$62.49$1,161,189.18View SEC Filing  
11/24/2015Samir Chandrakant PatelPresidentSell27,215$60.27$1,640,248.05View SEC Filing  
11/18/2015Nicholas GalakatosDirectorSell1,500$60.00$90,000.00View SEC Filing  
11/5/2015Samir Chandrakant PatelPresidentSell20,687$53.55$1,107,788.85View SEC Filing  
10/21/2015Samir Chandrakant PatelPresidentSell27,215$43.27$1,177,593.05View SEC Filing  
10/16/2015Barbara A. WoodSVPSell2,000$45.00$90,000.00View SEC Filing  
9/29/2015David R. GuyerCEOSell18,582$37.69$700,355.58View SEC Filing  
9/21/2015Samir Chandrakant PatelPresidentSell27,215$46.34$1,261,143.10View SEC Filing  
8/31/2015David R. GuyerCEOSell18,582$44.88$833,960.16View SEC Filing  
8/20/2015Samir Chandrakant PatelPresidentSell27,215$48.75$1,326,731.25View SEC Filing  
7/20/2015Samir Chandrakant PatelPresidentSell27,215$67.87$1,847,082.05View SEC Filing  
7/17/2015Glenn SblendorioDirectorSell3,000$67.33$201,990.00View SEC Filing  
7/1/2015Barbara A WoodSVPSell2,000$51.94$103,880.00View SEC Filing  
6/29/2015David R GuyerCEOSell18,582$51.05$948,611.10View SEC Filing  
6/18/2015Samir Chandrakant PatelPresidentSell12,000$49.78$597,360.00View SEC Filing  
5/28/2015David R GuyerCEOSell18,582$48.62$903,456.84View SEC Filing  
4/29/2015David R GuyerCEOSell18,582$48.45$900,297.90View SEC Filing  
4/17/2015Samir Chandrakant PatelPresidentSell12,000$50.47$605,640.00View SEC Filing  
3/30/2015Axel BolteDirectorBuy500$48.27$24,135.00View SEC Filing  
3/30/2015David R GuyerCEOSell18,582$48.26$896,767.32View SEC Filing  
3/2/2015Barbara A WoodSVPSell2,000$53.26$106,520.00View SEC Filing  
3/2/2015David R GuyerCEOSell18,582$53.22$988,934.04View SEC Filing  
1/2/2015David R GuyerCEOSell15,034$45.34$681,641.56View SEC Filing  
11/13/2014A/S NovoMajor ShareholderSell995,000$40.20$39,999,000.00View SEC Filing  
11/3/2014David R GuyerCEOSell15,034$39.71$597,000.14View SEC Filing  
10/2/2014David R GuyerCEOSell2,807$38.52$108,125.64View SEC Filing  
10/2/2014Samir Chandrakant PatelPresidentSell1,965$38.04$74,748.60View SEC Filing  
10/1/2014David R GuyerCEOSell12,227$37.30$456,067.10View SEC Filing  
10/1/2014Samir Chandrakant PatelPresidentSell17,676$37.28$658,961.28View SEC Filing  
9/4/2014David R GuyerCEOSell1,107$38.58$42,708.06View SEC Filing  
8/1/2014Bruce PeacockCFOSell6,191$37.78$233,895.98View SEC Filing  
8/1/2014David R GuyerCEOSell13,136$37.85$497,197.60View SEC Filing  
8/1/2014Samir Chandrakant PatelPresidentSell18,986$37.80$717,670.80View SEC Filing  
7/1/2014Bruce PeacockCFOSell7,739$41.07$317,840.73View SEC Filing  
7/1/2014David R GuyerCEOSell15,034$41.08$617,596.72View SEC Filing  
7/1/2014Samir Chandrakant PatelPresidentSell18,986$41.08$779,944.88View SEC Filing  
6/16/2014Nicholas GalakatosDirectorSell144,976$44.17$6,403,589.92View SEC Filing  
6/11/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell211,680$45.42$9,614,505.60View SEC Filing  
6/4/2014Svlsf Iv, LlcMajor ShareholderSell1,966,935$42.54$83,673,414.90View SEC Filing  
6/3/2014Bruce PeacockCFOSell13,931$40.12$558,911.72View SEC Filing  
6/3/2014Svlsf Iv, LlcMajor ShareholderSell1,865,619$40.65$75,837,412.35View SEC Filing  
6/2/2014David R GuyerCEOSell25,417$39.92$1,014,646.64View SEC Filing  
6/2/2014Samir Chandrakant PatelPresidentSell27,873$39.91$1,112,411.43View SEC Filing  
5/30/2014Svlsf Iv, LlcMajor ShareholderSell931,869$40.99$38,197,310.31View SEC Filing  
5/28/2014Svlsf Iv, LlcMajor ShareholderSell980,127$40.19$39,391,304.13View SEC Filing  
5/23/2014Svlsf Iv, LlcMajor ShareholderSell330,450$38.10$12,590,145.00View SEC Filing  
5/13/2014Hbm Healthcare Investments (Camajor shareholderSell500,000$29.75$14,875,000.00View SEC Filing  
5/1/2014Bruce PeacockCFOSell4,643$32.43$150,572.49View SEC Filing  
5/1/2014David GuyerCEOSell10,665$33.71$359,517.15View SEC Filing  
5/1/2014Samir Chandrakant PatelPresidentSell14,319$32.45$464,651.55View SEC Filing  
3/24/2014Bruce PeacockCFOSell6,137$34.77$213,383.49View SEC Filing  
3/24/2014David GuyerCEOSell12,027$34.53$415,292.31View SEC Filing  
3/24/2014Samir Chandrakant PatelPresidentSell16,876$34.54$582,897.04View SEC Filing  
2/18/2014Svlsf Iv, Llcmajor shareholderSell2,111,364$29.61$62,517,488.04View SEC Filing  
9/30/2013A/S NovoInsiderBuy455,000$22.00$10,010,000.00View SEC Filing  
9/30/2013Hbm Healthcare Investments (CaMajor ShareholderBuy228,000$22.00$5,016,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ophthotech Corp. (NASDAQ:OPHT)
DateHeadline
News IconOphthotech Corp (NASDAQ:OPHT) Analyst Estimates | The ... - The Independent Republic (NASDAQ:OPHT)
theindependentrepublic.com - August 23 at 6:49 PM
capitalcube.com logoETF’s with exposure to Ophthotech Corp. : August 23, 2016 (NASDAQ:OPHT)
www.capitalcube.com - August 23 at 6:48 PM
nasdaq.com logoOphthotech is Now Oversold (OPHT) (NASDAQ:OPHT)
www.nasdaq.com - August 19 at 6:34 PM
finance.yahoo.com logoOphthotech's Fovista Has Potential To Break Through The 'Therapeutic Ceiling' Of Anti-VEGF Therapies (NASDAQ:OPHT)
finance.yahoo.com - August 19 at 6:34 PM
fidaily.com logoBTIG Research Starts Coverage on Ophthotech Corporation (OPHT) Setting A Rating Of “Buy” (NASDAQ:OPHT)
www.fidaily.com - August 19 at 9:42 AM
News IconReal-World Anti-VEGF Data Disappointing (NASDAQ:OPHT)
www.medscape.com - August 11 at 7:07 PM
capitalcube.com logoOphthotech Corp. :OPHT-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 (NASDAQ:OPHT)
www.capitalcube.com - August 11 at 7:07 PM
capitalcube.com logoETF’s with exposure to Ophthotech Corp. : August 11, 2016 (NASDAQ:OPHT)
www.capitalcube.com - August 11 at 7:07 PM
finance.yahoo.com logoOPHTHOTECH CORP. Financials (NASDAQ:OPHT)
finance.yahoo.com - August 11 at 7:07 PM
nasdaq.com logoNotable Two Hundred Day Moving Average Cross - OPHT (NASDAQ:OPHT)
www.nasdaq.com - August 10 at 7:05 PM
capitalcube.com logoOphthotech Corp. breached its 50 day moving average in a Bearish Manner : OPHT-US : August 10, 2016 (NASDAQ:OPHT)
www.capitalcube.com - August 10 at 9:45 AM
biz.yahoo.com logoOPHTHOTECH CORP. Files SEC form 10-Q, Quarterly Report (NASDAQ:OPHT)
biz.yahoo.com - August 5 at 6:53 PM
finance.yahoo.com logoEdited Transcript of OPHT earnings conference call or presentation 3-Aug-16 12:00pm GMT (NASDAQ:OPHT)
finance.yahoo.com - August 4 at 9:50 AM
reuters.com logoBRIEF-Ophthotech Q2 loss per share $0.85 (NASDAQ:OPHT)
www.reuters.com - August 3 at 7:01 PM
biz.yahoo.com logoOphthotech Corp Earnings Call (Q2 2016) (NASDAQ:OPHT)
biz.yahoo.com - August 3 at 7:01 PM
twst.com logoOphthotech Corporation: Ophthotech Reports Second Quarter 2016 Financial and Operating Results (NASDAQ:OPHT)
www.twst.com - August 3 at 7:01 PM
streetinsider.com logoForm 8-K Ophthotech Corp. For: Jul 29 (NASDAQ:OPHT)
www.streetinsider.com - August 3 at 7:01 PM
biz.yahoo.com logoOphthotech Corp Earnings Call scheduled for 8:00 am ET today (NASDAQ:OPHT)
biz.yahoo.com - August 3 at 7:01 PM
streetinsider.com logoForm 8-K Ophthotech Corp. For: Jul 29 - StreetInsider.com (NASDAQ:OPHT)
www.streetinsider.com - August 3 at 9:55 AM
sg.finance.yahoo.com logoOphthotech reports 2Q loss (NASDAQ:OPHT)
sg.finance.yahoo.com - August 3 at 9:55 AM
biz.yahoo.com logoOPHTHOTECH CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Principal (NASDAQ:OPHT)
biz.yahoo.com - August 3 at 9:55 AM
publicnow.com logoOphthotech Reports Second Quarter 2016 Financial and Operating Results (NASDAQ:OPHT)
www.publicnow.com - August 3 at 9:55 AM
finance.yahoo.com logoOphthotech Announces Election of Ian F. Smith, Vertex Executive Vice President and Chief Financial Officer, to Its Board of Directors (NASDAQ:OPHT)
finance.yahoo.com - August 2 at 11:36 AM
seekingalpha.com logoBiotech Forum Daily Digest: Biotech Tries To Break Through Upward Resistance Levels (NASDAQ:OPHT)
seekingalpha.com - July 29 at 6:47 PM
businesswire.com logoOphthotech Corporation to Report Second Quarter 2016 Financial Results and Host Conference Call on Wednesday ... - Business Wire (press release) (NASDAQ:OPHT)
www.businesswire.com - July 25 at 11:06 AM
publicnow.com logoOphthotech Corporation to Report Second Quarter 2016 Financial Results and Host Conference Call on Wednesday, August 3, 2016 (NASDAQ:OPHT)
www.publicnow.com - July 25 at 8:28 AM
equities.com logoOphthotech Corporation (OPHT) Jumps 6.04% on July 20 - Equities.com (NASDAQ:OPHT)
www.equities.com - July 21 at 6:59 PM
News IconWhat's Ophthotech Corp Upside After Today's Gap Up? - Consumer Eagle (NASDAQ:OPHT)
www.consumereagle.com - July 21 at 6:59 PM
capitalcube.com logoETF’s with exposure to Ophthotech Corp. : July 19, 2016 (NASDAQ:OPHT)
www.capitalcube.com - July 19 at 12:56 PM
News IconOphthotech Corporation (NASDAQ:OPHT) Shorted Shares Decreased By 3.95% - Consumer Eagle (NASDAQ:OPHT)
www.consumereagle.com - July 18 at 12:06 PM
equities.com logoOphthotech Corporation (OPHT) Jumps 5.02% on July 15 - Equities.com (NASDAQ:OPHT)
www.equities.com - July 17 at 6:04 PM
news.cmlviz.com logoOphthotech Corporation Realized Volatility Hits Extreme Level - CML News (NASDAQ:OPHT)
news.cmlviz.com - July 15 at 11:41 AM
News IconHow Many Ophthotech Corp (NASDAQ:OPHT)'s Analysts Are Bearish? - Consumer Eagle (NASDAQ:OPHT)
www.consumereagle.com - July 15 at 11:40 AM
news.cmlviz.com logoOption Market: Ophthotech Corporation Risk Hits An Extreme High - CML News (NASDAQ:OPHT)
news.cmlviz.com - July 12 at 6:56 PM
seekingalpha.com logoBiotech ETF IBB Short Squeeze May Be Ahead (NASDAQ:OPHT)
seekingalpha.com - July 12 at 10:59 AM
News IconStock Performance Rundown on: Ophthotech Corporation (NASDAQ:OPHT) - Press Telegraph (NASDAQ:OPHT)
presstelegraph.com - July 10 at 5:59 PM
fiscalstandard.com logoNext Weeks Broker Price Targets For Ophthotech Corporation (NASDAQ:OPHT) - Fiscal Standard (NASDAQ:OPHT)
www.fiscalstandard.com - July 10 at 5:58 PM
news.cmlviz.com logoOphthotech Corporation Stock Momentum Hits Strength - CML News (NASDAQ:OPHT)
news.cmlviz.com - July 8 at 9:37 AM
fool.com logoAfter a 31% Decline, Can Shares of Ophthotech Inc. Bounce Back Later This Year? (NASDAQ:OPHT)
www.fool.com - July 5 at 8:21 AM
News IconShare Performance Recap for: Ophthotech Corporation (NASDAQ:OPHT) - Press Telegraph (NASDAQ:OPHT)
presstelegraph.com - July 3 at 6:02 PM
News IconOphthotech Corporation (NASDAQ:OPHT) Shorted Shares Decreased By 3.95% - Engelwood Daily (NASDAQ:OPHT)
www.engelwooddaily.com - June 28 at 11:30 AM
News IconOphthotech completes patient recruitment for third phase 3 trial of Fovista (NASDAQ:OPHT)
www.healio.com - June 23 at 7:11 PM
nasdaq.com logoAdd Up The Pieces: JKJ Could Be Worth $152 (NASDAQ:OPHT)
www.nasdaq.com - June 23 at 9:21 AM
reuters.com logoBRIEF-Ophthotech says achieved $30 mln enrollment milestone from Novartis Pharma (NASDAQ:OPHT)
www.reuters.com - June 20 at 6:29 PM
tradecalls.org logoCompany Shares of Ophthotech Corporation Drops by -6.28% - Trade Calls (NASDAQ:OPHT)
www.tradecalls.org - June 20 at 8:16 AM
publicnow.com logoOphthotech Completes Patient Recruitment in Phase 3 Trial of Fovista® Anti-PDGF Therapy in Combination with Eylea® or Avastin® in Wet Age-Related Macular Degeneration (NASDAQ:OPHT)
www.publicnow.com - June 20 at 7:49 AM
istreetwire.com logoAnalyst Activity: Ophthotech Corp (NASDAQ:OPHT) - iStreetWire (NASDAQ:OPHT)
istreetwire.com - June 18 at 5:56 PM
blogs.barrons.com logoMore Fovista Risk For Regeneron Than Investors Realize: Canaccord (NASDAQ:OPHT)
blogs.barrons.com - June 17 at 6:28 PM
seekingalpha.com logoOphthotech: Start Preparing For The Blockbuster - Fovista - Seeking Alpha (NASDAQ:OPHT)
seekingalpha.com - June 15 at 6:36 PM
seekingalpha.com logoOphthotech: Start Preparing For The Blockbuster - Fovista (NASDAQ:OPHT)
seekingalpha.com - June 15 at 11:13 AM

Social

Ophthotech Corp. (NASDAQ:OPHT) Chart for Friday, August, 26, 2016


Last Updated on 8/26/2016 by MarketBeat.com Staff